Q4 2025 Axsome Therapeutics Inc Earnings Call Transcript
Key Points
- Axsome Therapeutics Inc (AXSM) reported a 65% year-over-year increase in total revenue for the fourth quarter, reaching $196 million.
- AUVELITY achieved sales of over $0.5 billion in its third full year of launch, demonstrating strong market performance.
- The company has a robust CNS pipeline with 5 novel product candidates across nine high-impact indications.
- Axsome Therapeutics Inc (AXSM) has built a technologically enabled scalable commercial platform to support future growth.
- The company ended the year with $323 million in cash and cash equivalents, indicating a strong financial position.
- Net loss for the fourth quarter was $28.6 million, although this was an improvement from the previous year's loss.
- Research and development expenses were $48.8 million for the fourth quarter, reflecting ongoing high costs in advancing the pipeline.
- Selling, general, and administrative expenses increased by 39% year-over-year, driven by commercialization activities.
- Gross to net discounts for AUVELITY and SUNOSI are expected to increase to the mid-50% range, potentially impacting net revenue.
- SYMBRAVO's gross to net discount remains elevated in the high 70% range during its launch phase, affecting profitability.
Good morning, and welcome to the Axsome Therapeutics' fourth-quarter and full-year 2025 earnings conference call. My name is Kevin, and I'll be your operator for today's call. (Operator Instructions) Please note, this call is being recorded. I would now like to hand the call over to Ashley Dong, Director of Investor Relations. Ashley, please go ahead.
Thank you. Good morning, and thank you all for joining Axsome's fourth quarter and full year 2025 earnings conference call. With us today are Dr. Herriot Tabuteau, our Chief Executive Officer; Nick Pizzie, our Chief Financial Officer; and Ari Maizel, our Chief Commercial Officer, who will begin our call with prepared remarks. Mark Jacobson, our Chief Operating Officer; and Hunter Murdock, our General Counsel, will also be available for Q&A.
Before we begin, I encourage everyone to visit the Investors section of our website to find the press release and presentation for today's call. Please note that today's discussion includes forward-looking
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
